Flash Finance

Medplus Health Services LimitedMEDPLUSCorporate

Pharmacy Retail Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹611.95
MCap ₹7,349 Cr · P/E 33.5
Medplus Health Services Limited — Stock analysis & AI research Medplus Health Services Limited — Seasonality — best & worst months Medplus Health Services Limited — Technical indicators & charts Medplus Health Services Limited — Technical setup — score, trend, support & resistance Medplus Health Services Limited — Falling Wedge pattern forming Medplus Health Services Limited — Live exchange announcements
📋 High Profit Growth Stocks 📈 RSI Oversold Stocks📈 New 52-Week Low Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,864 Cr
Sales · Mar 2026
+23.4% YoY
₹169 Cr
Operating Profit · Mar 2026
+24.3% YoY
9.1%
OPM % · Mar 2026
+1.1% YoY
₹64 Cr
Net Profit · Mar 2026
+25.5% YoY
₹5.33
EPS · Mar 2026
+24.2% YoY

📝 Medplus Health Services Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Medplus Health Services Limited reported revenue of ₹1,864 crore for the quarter ended March 2026 (Q4 FY26), up 23.4% from ₹1,510 crore in the same quarter last year, and up 3.2% sequentially over the December 2025 quarter.

Net profit rose 25.5% year-on-year to ₹64 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹5.33.

Operating profit stood at ₹169 crore — an operating margin (OPM) of 9.1%, compared with 9.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Medplus Health Services Limited posted revenue of ₹6,892 crore, a growth of 12.3% over FY25, with a net profit of ₹220 crore (up 46.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹6,892 crore with a net profit of ₹220 crore.

Valuation snapshot

At the current price of ₹611.95, MEDPLUS has a market capitalisation of ₹7,349 crore and a trailing P/E of about 33.5.

Within the Pharmacy Retail industry, it is the largest of the 2 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 40.19%, foreign institutional investors (FIIs) 12.58%, domestic institutional investors (DIIs) 31.89%, public shareholders 15.29% of Medplus Health Services Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7,349 Cr
Current Price ?
₹612.0
P/E ?
33.46below ind
Industry P/E ?
43.60
P/B ?
3.72
P/S ?
1.07
P/FCF ?
19.70
Enterprise Value ?
₹8,773 Cr
EV/EBITDA ?
14.45
PEG ?
0.50
Earnings Yield ?
3.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹6,892 Cr
OPM ?
8.8%
Profit after tax (TTM) ?
₹220 Cr
EPS (TTM) ?
₹18.29
ROCE ?
13.0%
ROE ?
11.1%
ROA ?
5.6%
Growth
Sales — latest qtr ?
₹1,864 Cr
PAT — latest qtr ?
₹64 Cr
YoY qtr sales growth ?
23.4%
YoY qtr profit growth ?
25.5%
Sales growth (3y) ?
15%
Sales growth (5y) ?
18%
Profit growth (3y) ?
67%
Profit growth (5y) ?
29%
Financial Health
Debt ?
₹1,424 Cr
Debt to Equity ?
0.72
Interest Coverage ?
2.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.19%
Change in promoter holding ?
-0.13%
Pledged percentage ?
N/A
Market
Return 3 months ?
-23.6%
Return 6 months ?
-30.3%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 1,1901,2531,2841,4091,4411,4901,4891,5761,5611,5101,5431,6791,8061,864 +23.4% +3.2%
Operating Profit 728271859210694124133136131149159169 +24.3% +6.5%
Other Income 11149101010912131615171821 +31.2% +15.1%
Interest 2122232424252525262727293133 +22.2% +7.0%
Depreciation 4656525557596063626466697376 +18.8% +4.5%
Profit Before Tax 161751620321848576153697380 +31.1% +9.2%
Net Profit 132741514341439465142565864 +25.5% +10.7%
EPS 1.122.240.321.221.152.811.203.243.844.293.544.634.825.33 +24.2% +10.6%
OPM % 6.0% 6.5% 5.6% 6.0% 6.4% 7.1% 6.3% 7.9% 8.5% 9.0% 8.5% 8.9% 8.8% 9.1% +1.1% +3.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹6,136 Cr ₹6,892 Cr ₹6,892 Cr +12.3%
Operating Profit ₹487 Cr ₹607 Cr ₹607 Cr +24.8%
OPM % 7.93% 8.81% 8.81% +11.1%
NPM % 2.44% 3.19% 3.19% +30.7%
Other Income ₹49 Cr ₹72 Cr ₹72 Cr +46.9%
Depreciation ₹250 Cr ₹283 Cr ₹283 Cr +13.3%
Interest ₹103 Cr ₹120 Cr ₹120 Cr +16.8%
EBIT ₹237 Cr ₹324 Cr ₹324 Cr +36.8%
PBT ₹183 Cr ₹275 Cr ₹275 Cr +50.1%
Tax ₹23 Cr ₹39 Cr ₹39 Cr +69.2%
Net Profit ₹150 Cr ₹220 Cr ₹220 Cr +46.5%
EPS ₹12.57 ₹18.32 ₹18.32 +45.7%
Material Cost ₹3,478 Cr ₹3,698 Cr ₹3,698 Cr +6.3%
Employee Cost ₹532 Cr ₹646 Cr ₹646 Cr +21.5%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242424 +0.0%
Reserves 1,4671,5541,7171,951 +13.6%
Borrowings 9001,0101,1201,424 +27.1%
Other Liabilities 406417500533 +6.6%
Total Liabilities 2,7973,0053,3603,933 +17.1%
Fixed Assets 1,1381,2421,2961,595 +23.1%
CWIP 25111632 +100.0%
Investments 0000 —
Other Assets 1,6331,7522,0472,306 +12.7%
Total Assets 2,7973,0053,3603,933 +17.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 90144540496 -8.1%
Cash from Investing Activity 429-83-318-128 +59.7%
Cash from Financing Activity -170-198-228-256 -12.3%
Net Cash Flow 350-137-5112 +2340.0%
Free Cash Flow -7861482373 -22.6%
CFO/OP 39%49%120%94% -21.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1111 +0.0%
Inventory Days 11711110699 -6.6%
Days Payable 27212422 -8.3%
Cash Conversion Cycle 91928379 -4.8%
Working Capital Days 58585449 -9.3%
ROCE % 5%7%10%13% +30.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 40.32%40.29%40.29%40.22%40.19%40.19% +0.0%
FIIs 16.43%16.53%16.83%15.53%14.38%12.58% -12.5%
DIIs 26.03%26.51%26.58%27.82%29.95%31.89% +6.5%
Public 17.18%16.60%16.27%16.41%15.44%15.29% -1.0%
Others 0.05%0.05%0.04%0.04%—— —
No. of Shareholders 81,74278,33779,15777,27876,00577,714 +2.2%

⚖️ Peer comparison

Industry: Pharmacy Retail · 2 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 MEDPLUS Medplus Health ₹660.00 7,926 36.0 6,892 220 8.8% 3.2% 12.3% 46.5% 23.4% 25.5%
2 ENTERO Entero Healthcare ₹1,731.80 7,537 58.8 7,128 168 4.4% 2.4% 29.4% 36.3% 38.2% 72.2%
❓ Frequently asked questions
What was Medplus Health Services Limited's revenue in Q4 FY26?
Medplus Health Services Limited reported revenue of ₹1,864 crore for the quarter ended March 2026 (Q4 FY26), up 23.4% from ₹1,510 crore in the same quarter last year, and up 3.2% sequentially over the December 2025 quarter.
What was Medplus Health Services Limited's net profit in Q4 FY26?
Net profit rose 25.5% year-on-year to ₹64 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹5.33.
What is MEDPLUS's market capitalisation and P/E ratio?
At the current price of ₹611.95, MEDPLUS has a market capitalisation of ₹7,349 crore and a trailing P/E of about 33.5.
Who owns Medplus Health Services Limited? (shareholding pattern)
As of Sep 2026, promoters held 40.19%, foreign institutional investors (FIIs) 12.58%, domestic institutional investors (DIIs) 31.89%, public shareholders 15.29% of Medplus Health Services Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI